No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.
Identifieur interne : 000623 ( PubMed/Corpus ); précédent : 000622; suivant : 000624No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.
Auteurs : Chizoba C. Umeh ; Adriana Pérez ; Erika F. Augustine ; Rohit Dhall ; Richard B. Dewey ; Zoltan Mari ; David K. Simon ; Anne-Marie A. Wills ; Chadwick W. Christine ; Jay S. Schneider ; Oksana SuchowerskySource :
- PloS one [ 1932-6203 ] ; 2014.
English descriptors
- KwdEn :
- Aged, Canada, Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Female, Humans, Levodopa (administration & dosage), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Severity of Illness Index, Sex Factors, Treatment Outcome, United States.
- MESH :
- chemical , administration & dosage : Dopamine Agents, Levodopa.
- chemical , therapeutic use : Dopamine Agents, Levodopa.
- geographic : Canada, United States.
- diagnosis : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Severity of Illness Index, Sex Factors, Treatment Outcome.
Abstract
Sex differences in Parkinson disease clinical features have been reported, but few studies have examined sex influences on use of dopaminergic medication in early Parkinson disease. The objective of this study was to test if there are differences in the type of dopaminergic medication used and levodopa equivalent daily dose between men and women with early Parkinson disease enrolled in a large multicenter study of Creatine as a potential disease modifying therapy - the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson Disease Long-Term Study-1.
DOI: 10.1371/journal.pone.0112287
PubMed: 25486269
Links to Exploration step
pubmed:25486269Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.</title><author><name sortKey="Umeh, Chizoba C" sort="Umeh, Chizoba C" uniqKey="Umeh C" first="Chizoba C" last="Umeh">Chizoba C. Umeh</name><affiliation><nlm:affiliation>Department of Neurology and Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Perez, Adriana" sort="Perez, Adriana" uniqKey="Perez A" first="Adriana" last="Pérez">Adriana Pérez</name><affiliation><nlm:affiliation>Department of Biostatistics, The University of Texas School of Public Health, Austin, Texas, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Augustine, Erika F" sort="Augustine, Erika F" uniqKey="Augustine E" first="Erika F" last="Augustine">Erika F. Augustine</name><affiliation><nlm:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Dhall, Rohit" sort="Dhall, Rohit" uniqKey="Dhall R" first="Rohit" last="Dhall">Rohit Dhall</name><affiliation><nlm:affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Dewey, Richard B" sort="Dewey, Richard B" uniqKey="Dewey R" first="Richard B" last="Dewey">Richard B. Dewey</name><affiliation><nlm:affiliation>Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Mari, Zoltan" sort="Mari, Zoltan" uniqKey="Mari Z" first="Zoltan" last="Mari">Zoltan Mari</name><affiliation><nlm:affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Simon, David K" sort="Simon, David K" uniqKey="Simon D" first="David K" last="Simon">David K. Simon</name><affiliation><nlm:affiliation>Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Wills, Anne Marie A" sort="Wills, Anne Marie A" uniqKey="Wills A" first="Anne-Marie A" last="Wills">Anne-Marie A. Wills</name><affiliation><nlm:affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W" last="Christine">Chadwick W. Christine</name><affiliation><nlm:affiliation>Department of Neurology, University of California San Francisco, San Francisco, California, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Schneider, Jay S" sort="Schneider, Jay S" uniqKey="Schneider J" first="Jay S" last="Schneider">Jay S. Schneider</name><affiliation><nlm:affiliation>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation><nlm:affiliation>Departments of Medicine (Neurology), Medical Genetics and Pediatrics, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25486269</idno><idno type="pmid">25486269</idno><idno type="doi">10.1371/journal.pone.0112287</idno><idno type="wicri:Area/PubMed/Corpus">000623</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000623</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.</title><author><name sortKey="Umeh, Chizoba C" sort="Umeh, Chizoba C" uniqKey="Umeh C" first="Chizoba C" last="Umeh">Chizoba C. Umeh</name><affiliation><nlm:affiliation>Department of Neurology and Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Perez, Adriana" sort="Perez, Adriana" uniqKey="Perez A" first="Adriana" last="Pérez">Adriana Pérez</name><affiliation><nlm:affiliation>Department of Biostatistics, The University of Texas School of Public Health, Austin, Texas, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Augustine, Erika F" sort="Augustine, Erika F" uniqKey="Augustine E" first="Erika F" last="Augustine">Erika F. Augustine</name><affiliation><nlm:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Dhall, Rohit" sort="Dhall, Rohit" uniqKey="Dhall R" first="Rohit" last="Dhall">Rohit Dhall</name><affiliation><nlm:affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Dewey, Richard B" sort="Dewey, Richard B" uniqKey="Dewey R" first="Richard B" last="Dewey">Richard B. Dewey</name><affiliation><nlm:affiliation>Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Mari, Zoltan" sort="Mari, Zoltan" uniqKey="Mari Z" first="Zoltan" last="Mari">Zoltan Mari</name><affiliation><nlm:affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Simon, David K" sort="Simon, David K" uniqKey="Simon D" first="David K" last="Simon">David K. Simon</name><affiliation><nlm:affiliation>Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Wills, Anne Marie A" sort="Wills, Anne Marie A" uniqKey="Wills A" first="Anne-Marie A" last="Wills">Anne-Marie A. Wills</name><affiliation><nlm:affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W" last="Christine">Chadwick W. Christine</name><affiliation><nlm:affiliation>Department of Neurology, University of California San Francisco, San Francisco, California, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Schneider, Jay S" sort="Schneider, Jay S" uniqKey="Schneider J" first="Jay S" last="Schneider">Jay S. Schneider</name><affiliation><nlm:affiliation>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation><nlm:affiliation>Departments of Medicine (Neurology), Medical Genetics and Pediatrics, University of Alberta, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Canada</term><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Severity of Illness Index</term><term>Sex Factors</term><term>Treatment Outcome</term><term>United States</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Sex Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sex differences in Parkinson disease clinical features have been reported, but few studies have examined sex influences on use of dopaminergic medication in early Parkinson disease. The objective of this study was to test if there are differences in the type of dopaminergic medication used and levodopa equivalent daily dose between men and women with early Parkinson disease enrolled in a large multicenter study of Creatine as a potential disease modifying therapy - the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson Disease Long-Term Study-1.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25486269</PMID><DateCreated><Year>2014</Year><Month>12</Month><Day>09</Day></DateCreated><DateCompleted><Year>2015</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.</ArticleTitle><Pagination><MedlinePgn>e112287</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0112287</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sex differences in Parkinson disease clinical features have been reported, but few studies have examined sex influences on use of dopaminergic medication in early Parkinson disease. The objective of this study was to test if there are differences in the type of dopaminergic medication used and levodopa equivalent daily dose between men and women with early Parkinson disease enrolled in a large multicenter study of Creatine as a potential disease modifying therapy - the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson Disease Long-Term Study-1.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Baseline data of 1,741 participants from 45 participating sites were analyzed. Participants from the United States and Canada were enrolled within five years of Parkinson Disease diagnosis. Two outcome variables were studied: type of dopaminergic medication used and levodopa equivalent daily dose at baseline in the Long-Term Study-1. Chi-square statistic and linear regression models were used for statistical analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no statistically significant differences in the frequency of use of different types of dopaminergic medications at baseline between men and women with Parkinson Disease. A small but statistically significant difference was observed in the median unadjusted levodopa equivalent daily dose at baseline between women (300 mg) and men (325 mg), but this was not observed after controlling for disease duration (years since Parkinson disease diagnosis), disease severity (Unified Parkinson's Disease Rating Scale Motor and Activities of Daily Living Scores), and body weight.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this large multicenter study, we did not observe sex differences in the type and dose of dopaminergic medications used in early Parkinson Disease. Further research is needed to evaluate the influence of male or female sex on use of dopaminergic medication in mid- and late-stage Parkinson Disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Umeh</LastName><ForeName>Chizoba C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, The University of Texas School of Public Health, Austin, Texas, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augustine</LastName><ForeName>Erika F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhall</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewey</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mari</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>David K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wills</LastName><ForeName>Anne-Marie A</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christine</LastName><ForeName>Chadwick W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Jay S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchowersky</LastName><ForeName>Oksana</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Departments of Medicine (Neurology), Medical Genetics and Pediatrics, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 NS066098</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 MD001779</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 NS044545</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NS043128</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2000 May 18;342(20):1484-91</RefSource><PMID Version="1">10816186</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2014 Jan 14;82(2):163-71</RefSource><PMID Version="1">24336138</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Law Med Ethics. 2001 Spring;29(1):13-27</RefSource><PMID Version="1">11521267</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2002 Mar-Apr;25(2):79-82</RefSource><PMID Version="1">11981233</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Hypotheses. 1994 Apr;42(4):280-2</RefSource><PMID Version="1">8072437</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1996 Jan;39(1):37-45</RefSource><PMID Version="1">8572664</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1998 Mar-Apr;21(2):118-21</RefSource><PMID Version="1">9579298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1999 Apr 22;52(7):1417-21</RefSource><PMID Version="1">10227628</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Dec 9;351(24):2498-508</RefSource><PMID Version="1">15590952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2005 Mar 15;45(6):832-7</RefSource><PMID Version="1">15766815</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2005 Oct;252(10):1201-5</RefSource><PMID Version="1">16151602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Rev Neurother. 2006 Mar;6(3):407-16</RefSource><PMID Version="1">16533144</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):819-24</RefSource><PMID Version="1">17098842</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2008 Oct;7(10):915-26</RefSource><PMID Version="1">18722812</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurol. 2010 Feb;17(2):260-6</RefSource><PMID Version="1">20039939</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Nov 15;25(15):2649-53</RefSource><PMID Version="1">21069833</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2011 Dec;17(10):757-60</RefSource><PMID Version="1">21824799</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2012 Oct;27(12):1513-21</RefSource><PMID Version="1">23079770</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Jul;28(8):1064-71</RefSource><PMID Version="1">23630119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2000 Jun 27;54(12):2292-8</RefSource><PMID Version="1">10881255</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4259292</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25486269</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0112287</ArticleId><ArticleId IdType="pii">PONE-D-14-26716</ArticleId><ArticleId IdType="pmc">PMC4259292</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000623 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000623 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25486269
|texte= No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25486269" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |